Navigation Links
Thomson Reuters Publishes Three Pharma Matters Reports Covering the Third Quarter of 2008
Date:1/21/2009

Quarterly Reports Use Market Intelligence and Competitive Analysis from Thomson Reuters to Highlight Developments in the Global Pharmaceutical Industry

PHILADELPHIA and LONDON, Jan. 21 /PRNewswire/ -- Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, has announced the availability of three Pharma Matters reports covering the time period July - September 2008. The quarterly Pharma Matters series covers all aspects of the pharmaceutical pipeline, leveraging strategic intelligence and competitive analysis from Thomson Pharma(R), Newport Horizon Premium(TM) and the Thomson Messaging Mapping System(SM).

The Ones to Watch - A Thomson Reuters quarterly review of the latest phase changes in the pharmaceutical pipeline, this report is based on strategic data and analysis from Thomson Pharma, the world's leading pharmaceutical competitive intelligence solution. In the report covering Q3 2008, the top five most promising drugs launched or receiving approval were:

    DRUG          DISEASE                     COMPANY

    Zeftera(TM)   Complicated skin and soft   Basilea Pharmaceutica
                  tissue infections

    Firazyr(R)    Hereditary angioedema       Jerini

    Bridion(R)    Reversal of muscle          Schering-Plough
                  relaxants

    Cleviprex(TM) Perioperative               The Medicines Company
                  hypertension

    Xarelto(R)    Venous thromboembolic       Bayer/Ortho-McNeil
                  events                      Pharmaceutical

More analysis, as well as information on drugs entering clinical Phases I, II and III are available in the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008totw_q3.pdf.

Movers and Shakers - This report covers the US generics industry using data and analysis from Newport Horizon Premium, the critical product targeting the global business development system. Analysis from the Q3 2008 report includes:

  • The pharmaceutical marketplace continued to demonstrate volatility, and the pace of patent challenges showed no sign of slackening in the third quarter of 2008.
  • During the third quarter of 2008, final approvals were issued on only 77 'A'-rated ANDAs, plummeting down from 142 the quarter before. First-time approvals of generic products by the FDA also dropped from 11 to 8 this quarter.
  • Seven new products (three combination products and four single active ingredient products) were subjected to paragraph IV challenges for the first time in Q3 2008, identical to the previous quarter.
  • Indian groups were in first place in terms of ANDA approvals during Q3 2008. Twelve India-based corporations received a total of 17 final ANDA approvals.
  • In the same time period, 11 US-based companies received a total of 15 approvals, putting the U.S. in second place for this quarter.
  • Mylan of the U.S. and Boehringer Ingelheim of Germany received the most final ANDA approvals (seven each).

To learn more about companies making their mark on the U.S. generics market, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008ms_q3.pdf

Who is Making the Biggest Splash? - A Thomson Reuters expert review of the organizations that are helping to shape professional opinions on drugs and therapies, using the unique insights of the Thomson Message Mapping System. In this quarterly review of the scientific literature on drugs and therapies, Thomson Reuters assesses the quantity and quality of the materials published by pharmaceutical companies, research institutions and other non-commercial bodies. The top five of the 15 listed organizations that have made the biggest impact as the leading sources of information on medical research from July - September 2008 are:

  1. Novartis
  2. Bristol-Meyers Squibb
  3. Eli Lilly
  4. Pfizer
  5. AstraZeneca

To see the complete list, as well as analysis and methodology, click here to read the full report: http://thomsonreuters.com/content/PDF/scientific/pharma/2008wmtbs_q3.pdf

To sign up for the Thomson Reuters Pharma Matters series of publications visit: http://scientific.thomsonreuters.com/forms/matters/

About Thomson Reuters

Thomson Reuters is the world's leading source of intelligent information for businesses and professionals. We combine industry expertise with innovative technology to deliver critical information to leading decision makers in the financial, legal, tax and accounting, scientific, healthcare and media markets, powered by the world's most trusted news organization. With headquarters in New York and major operations in London and Eagan, Minnesota, Thomson Reuters employs more than 50,000 people in 93 countries. For more information, go to thomsonreuters.com.


'/>"/>
SOURCE Thomson Reuters
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Thomson Scientific Predicts Nobel Laureates
2. Thomson Scientific Announces BONDplus for Biological Researchers
3. Hospitals Improve Survival Rates While Treating Sicker Patients Thomson Healthcare Study Shows
4. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
5. Thomson Healthcare Endorsed as Preferred Vendor of Information Products and Services for Virginia Hospitals
6. Thomson Acquires Prous Science
7. Common Early-Warning Symptoms of Ovarian Cancer Identified in CDC/Thomson Healthcare Study
8. Thomson Scientific Ranks Australian Universities and Research Institutes
9. Thomson Scientific Launches Confessions ... of a User Campaign Asking Are You the New Face of Research?
10. Contract Renewal Extends Thomson Healthcares Long-Standing Relationship with University Hospitals
11. Thomson Healthcare Launches Application That Assesses Physician Performance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal their ... Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. , ... Pro X users can now reveal the media of their split screens with ...
(Date:6/27/2016)... , ... June 27, 2016 , ... TopConsumerReviews.com recently awarded ... Eyeglasses . , Millions of individuals in the United States and Canada wear ... a way to both correct vision and make a fashion statement. Even celebrities use ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs ... College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. ... treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... to their offering. The ... commercial environment for MedImmune to enter. The US ageing population ... to drive considerable growth for effective anti-influenza medications. The introduction ... considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)... PRINCETON, N.J. , June 23, 2016  Guerbet ... of Premier Inc.,s Supplier Horizon Award . ... this year, Guerbet was recognized for its support of ... value creation through clinical excellence, and commitment to lower ... delighted to receive this recognition of our outstanding customer ...
Breaking Medicine Technology: